Hill June 8, 2024
The Food and Drug Administration (FDA) recently approved an expansion of a respiratory syncytial virus (RSV) vaccine for use in at-risk adults over the age of 50.
GSK, the vaccine’s maker, announced the approval Friday, making it the first vaccine rubber-stamped for adults ages 50-59 to protect against the virus.
“Today’s approval reflects the importance of broadening the benefits of RSV immunization to adults aged 50-59 who are at increased risk,” Tony Wood, GSK’s chief scientific officer, said in a statement. “For those with underlying medical conditions, RSV can have serious consequences, so we are proud to be the first to help protect them from RSV-LRTD.”
The pharmaceutical company requested the expansion in early February, saying their trial...
Today's Sponsors
Today's Sponsor